6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
14m ago	MSCI Announces Dates for 2026 Annual Market Classification and Accessibility Reviews
15m ago	CanCambria Energy Announces Participation in 2026 Louisiana Energy Conference
15m ago	Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
15m ago	Amex Exploration Raises C$59 Million in Total as it Closes Second Tranche of Private Placement
16m ago	GR Silver Provides a Corporate Update

About

10.60HKD+0.15 +1.44%

Closed • Updated at 22:16 GMT+00:00

Market Cap$3.46B

P/E Ratio18.08

Volume4.47M

Beta0.52

RSI26.02

Gross Margin81.62%

Health TechnologyPharmaceuticals: Major

Simcere Pharmaceutical Group Limited — investor relations, events, news, and company updates on 6ix.

Latest News

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Community Chat

Ask AI